PRMT1 通过甲基化 PHGDH 维持从头脂肪酸合成以驱动三阴性乳腺癌的化疗耐药性。

PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer.

机构信息

Department of Biochemistry, Keio University School of Medicine, Tokyo, Japan.

Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

出版信息

Cancer Res. 2024 Apr 1;84(7):1065-1083. doi: 10.1158/0008-5472.CAN-23-2266.

Abstract

UNLABELLED

Triple-negative breast cancer (TNBC) chemoresistance hampers the ability to effectively treat patients. Identification of mechanisms driving chemoresistance can lead to strategies to improve treatment. Here, we revealed that protein arginine methyltransferase-1 (PRMT1) simultaneously methylates D-3-phosphoglycerate dehydrogenase (PHGDH), a critical enzyme in serine synthesis, and the glycolytic enzymes PFKFB3 and PKM2 in TNBC cells. 13C metabolic flux analyses showed that PRMT1-dependent methylation of these three enzymes diverts glucose toward intermediates in the serine-synthesizing and serine/glycine cleavage pathways, thereby accelerating the production of methyl donors in TNBC cells. Mechanistically, PRMT1-dependent methylation of PHGDH at R54 or R20 activated its enzymatic activity by stabilizing 3-phosphoglycerate binding and suppressing polyubiquitination. PRMT1-mediated PHGDH methylation drove chemoresistance independently of glutathione synthesis. Rather, activation of the serine synthesis pathway supplied α-ketoglutarate and citrate to increase palmitate levels through activation of fatty acid synthase (FASN). Increased palmitate induced protein S-palmitoylation of PHGDH and FASN to further enhance fatty acid synthesis in a PRMT1-dependent manner. Loss of PRMT1 or pharmacologic inhibition of FASN or protein S-palmitoyltransferase reversed chemoresistance in TNBC. Furthermore, IHC coupled with imaging MS in clinical TNBC specimens substantiated that PRMT1-mediated methylation of PHGDH, PFKFB3, and PKM2 correlates with chemoresistance and that metabolites required for methylation and fatty acid synthesis are enriched in TNBC. Together, these results suggest that enhanced de novo fatty acid synthesis mediated by coordinated protein arginine methylation and protein S-palmitoylation is a therapeutic target for overcoming chemoresistance in TNBC.

SIGNIFICANCE

PRMT1 promotes chemoresistance in TNBC by methylating metabolic enzymes PFKFB3, PKM2, and PHGDH to augment de novo fatty acid synthesis, indicating that targeting this axis is a potential treatment strategy.

摘要

未标记

三阴性乳腺癌(TNBC)的化疗耐药性阻碍了有效治疗患者的能力。确定驱动化疗耐药性的机制可以导致改善治疗的策略。在这里,我们揭示了蛋白质精氨酸甲基转移酶 1(PRMT1)同时甲基化 D-3-磷酸甘油酸脱氢酶(PHGDH),这是丝氨酸合成中的关键酶,以及 TNBC 细胞中的糖酵解酶 PFKFB3 和 PKM2。13C 代谢通量分析表明,这三种酶的 PRMT1 依赖性甲基化将葡萄糖转向丝氨酸合成和丝氨酸/甘氨酸裂解途径中的中间产物,从而加速 TNBC 细胞中甲硫氨酸供体的产生。在机制上,PRMT1 依赖性甲基化 PHGDH 的 R54 或 R20 通过稳定 3-磷酸甘油酸结合和抑制多聚泛素化来激活其酶活性。PRMT1 介导的 PHGDH 甲基化独立于谷胱甘肽合成驱动化疗耐药性。相反,通过激活脂肪酸合酶(FASN),丝氨酸合成途径的激活供应α-酮戊二酸和柠檬酸,以增加棕榈酸水平。增加的棕榈酸诱导 PHGDH 和 FASN 的蛋白 S-棕榈酰化,以进一步以 PRMT1 依赖的方式增强脂肪酸合成。PRMT1 的缺失或 FASN 或蛋白 S-棕榈酰转移酶的药理学抑制逆转了 TNBC 的化疗耐药性。此外,临床 TNBC 标本中的 IHC 与成像 MS 的结合证实,PRMT1 介导的 PHGDH、PFKFB3 和 PKM2 的甲基化与化疗耐药性相关,并且用于甲基化和脂肪酸合成的代谢物在 TNBC 中富集。总之,这些结果表明,协调的蛋白质精氨酸甲基化和蛋白 S-棕榈酰化介导的增强的从头脂肪酸合成是克服 TNBC 化疗耐药性的治疗靶点。

意义

PRMT1 通过甲基化代谢酶 PFKFB3、PKM2 和 PHGDH 促进 TNBC 的化疗耐药性,从而增加从头脂肪酸合成,表明靶向该轴是一种潜在的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d5e/10982647/4d61dac4fe00/overview_graphic_can-23-2266.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索